test3

M. Adham Salkeni, MD, FRCPC

Virginia Cancer Specialists Physicians

M. Adham Salkeni, MD, FRCPC Headshot

Caring for cancer patients is my passion and inspiration as a physician. I strive to make clinical trials available to all patients because clinical trials are the only path to finding a cure, and because - where there is life there is hope.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist, Virginia Cancer Specialists Research Institute

Board Certification

Medical Oncology, Hematology and Internal Medicine

Fellowship

Advanced Developmental Therapeutics, National Cancer Institute, National Institutes of Health Hematology and Oncology, University of Cincinnati

Residency

Saint Louis University School of Medicine

Medical School

University of Damascus School of Medicine, Damascus, Syria

Special Interests

Clinical Trials

Mohamad Adham Salkeni, MD, FRCPC earned his medical degree from the University of Damascus. He then completed his residency in internal medicine at St. Louis University and fellowship in hematology and oncology at the University of Cincinnati. During his medical training, he was engaged in bench and translational research investigating inflammatory modulation of the blood-brain barrier in vivo, published in the Journal of Neuroimmune Pharmacology; and established a tumor-informed assay for detecting circulating mutant DNA of brain cancer, published in the Journal of Neuro-Oncology. Following training completion, he joined West Virginia University as an Assistant Professor and was later promoted to Associate Professor, where he also served as Medical Director for the Clinical Trials Research Unit and Co-Chair of the Breast Cancer Leadership Committee. Interested in early drug development, Dr. Salkeni elected to move on to the National Cancer Institute, National Institutes of Health (NCI/NIH) in Bethesda, Maryland, where he completed a fellowship in Advanced Developmental Therapeutics. During his time spent at the NCI, he participated in concept development and design of early phase clinical trials of novel immunotherapeutics and small molecules, and authored a book chapter on resistance mechanisms to immunotherapy.

Dr. Salkeni is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). Dr. Salkeni joined Virginia Cancer Specialists as a Clinical Investigator in Phase 1 cancer clinical trials, in collaboration with NEXT Oncology.
In his spare time, he enjoys swimming and spending time outdoors with family.

Physician Publications

October 10, 2022

A case of strand migration after prostate seed implant

Read More
June 15, 2022

Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Read More
June 1, 2022

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Read More

More Publications by M. Adham Salkeni, MD, FRCPC

January 1, 2022

Resistance to Immunotherapy: Mechanisms and Means for Overcoming

Read More
December 1, 2021

Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer

Read More
December 1, 2021

Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer

Read More
October 12, 2021

Guest Editor and Reviewer Acknowledgments: 2021

Read More
September 24, 2021

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Read More
June 15, 2021

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer

Read More
January 1, 2021

Resistance to Immunotherapy: Mechanisms and Means for Overcoming

Read More
January 1, 2021

Resistance to Immunotherapy: Mechanisms and Means for Overcoming

Read More
November 3, 2020

Guest Editor and Reviewer Acknowledgments: 2020

Read More
October 10, 2019

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Read More
September 20, 2019

Understanding palbociclib practice patterns in a real-world setting.

Read More
April 1, 2019

NEDD9 adaptor protein regulates HER2-driven metastasis in breast cancer

Read More
March 8, 2019

The Stem Cell Phenotype of Aggressive Breast Cancer Cells

Read More
February 15, 2019

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

Read More
February 1, 2019

Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease

Read More
January 1, 2019

Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting

Read More
December 1, 2018

Switching endocrine therapy in breast cancer as a strategy for musculoskeletal symptoms, tolerance, and adherence.

Read More
October 10, 2018

First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study

Read More
October 1, 2018

Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy

Read More
May 20, 2018

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).

Read More
October 1, 2017

Metastatic breast cancer: Endocrine therapy landscape reshaped

Read More
June 1, 2017

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Read More
May 20, 2017

Prognostic factors in breast cancer patients evaluated by PET/CT prior to neoadjuvant chemotherapy.

Read More
May 20, 2017

Retrospective analysis of the role of CA 15-3 as a biomarker for breast cancer relapse.

Read More
March 29, 2017

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Read More
March 1, 2017

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

Read More
October 10, 2016

Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC)

Read More
August 15, 2016

Abstract B20: Development of metastatic patient-derived xenografts (PDXs) for accurate assessment of anti-metastatic therapeutics in pre-clinical settings

Read More
August 1, 2016

Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer

Read More
May 20, 2016

Longitudinal study of arm impairments, function and quality of life following mastectomy.

Read More
April 1, 2016

Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses

Read More
March 16, 2016

Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses

Read More
August 11, 2015

Resolution of Telangiectasia Macularis Eruptiva Perstans with successful treatment of synchronous large granular lymphocytic leukemia

Read More
May 1, 2015

Optimal management of sentinel lymph node positive biopsy patients in early breast cancer

Read More
March 19, 2015

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer

Read More
March 1, 2015

P1.14 - A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies

Read More
February 15, 2015

Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10

Read More
November 15, 2014

MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1

Read More
October 16, 2014

MicroRNAs 206 and 21 Cooperate To Promote RAS–Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1

Read More
October 1, 2013

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

Read More
July 23, 2013

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

Read More
May 20, 2013

Patient selection for anti-EGFViii therapies in glioblastoma multiforme (GBM): Use of circulating tumor DNA.

Read More
May 20, 2013

BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study.

Read More
April 11, 2013

Bevacizumab and Glioblastoma Multiforme: A Thrombosis and Bleeding Dilemma (A Case Report and a Brief Review of the Literature).

Read More
March 1, 2013

Patient Selection for Anti-Egfviii Therapies in Glioblastoma Multiforme (GBM): Use of Circulating Tumor DNA

Read More
May 20, 2012

Identification of a new mutation in the EGFR ligand-binding domain: Predictive factor for cetuximab antitumor activity in head and neck carcinoma?

Read More
May 5, 2012

A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.

Read More
June 1, 2009

Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways

Read More
November 28, 2008

Lipopolysaccharide Impairs Blood–Brain Barrier P-glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-Independent Pathways

Read More

Clinical Trials (10)

Clinical Trial CG-745-2-08

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy


Clinical Trial C-800-22

"A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL + GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (AGEN1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN + IRINOTECAN + OXALIPLATIN (FOLFIRINOX)"


Clinical Trial TT-10-101

Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors


Clinical Trial PRT3645

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors


Clinical Trial NM1F-T1

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors


Clinical Trial IMM-1-104

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

All Clinical Trials for M. Adham Salkeni, MD, FRCPC

Clinical Trial CG-745-2-08

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05249101

ClinicalTrials.gov Link:

Click Here


Clinical Trial C-800-22

“A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +
GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (AGEN1181) IN PATIENTS
WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON
PRIOR 5FU + LEUCOVORIN + IRINOTECAN + OXALIPLATIN (FOLFIRINOX)”

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05630183

ClinicalTrials.gov Link:

Click Here


Clinical Trial TT-10-101

Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04969315

ClinicalTrials.gov Link:

Click Here


Clinical Trial PRT3645

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05538572

ClinicalTrials.gov Link:

Click Here


Clinical Trial NM1F-T1

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05746897

ClinicalTrials.gov Link:

Click Here


Clinical Trial IMM-1-104

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05585320

ClinicalTrials.gov Link:

Click Here


Clinical Trial HFB-301001

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05229601

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS1103-074

A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

ClinicalTrials.gov ID:

NCT05765851

ClinicalTrials.gov Link:

Click Here


Clinical Trial BBP 398 (NAV-1001)

A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05375084

ClinicalTrials.gov Link:

Click Here


Clinical Trial ABBV400

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT05029882

ClinicalTrials.gov Link:

Click Here

Primary Location

Fairfax Office Office

Fairfax Office

Learn More